Article

Prevalence of cardiovascular risk factors in patients with psoriasis

Dermatology, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA.
Journal of the American Academy of Dermatology (Impact Factor: 5). 12/2006; 55(5):829-35. DOI: 10.1016/j.jaad.2006.08.040
Source: PubMed

ABSTRACT Previous studies suggest that patients hospitalized for psoriasis have an increased frequency of a variety of cardiovascular comorbidities. Limited population-based data exist on this association, and few studies have determined which factors are independently associated with psoriasis.
We sought to determine whether the prevalence of the major cardiovascular risk factors was higher in mild and severe psoriasis than in patients without psoriasis.
We conducted a population-based study in the United Kingdom using the General Practice Research Database. Patients were classified as having severe psoriasis if they received a code for psoriasis as well as systemic therapy. Patients were defined as having mild psoriasis if they ever received a psoriasis code but no systemic therapy. Control subjects were selected from the same practices and start dates as psoriasis patients. Patients were classified as having risk factors if they received codes for diabetes, hypertension, hyperlipidemia, obesity, or smoking. Analyses were performed by using conditional logistic regression, and adjustments were made considering age, gender, person-years, and all cardiovascular risk factors.
We identified 127,706 patients with mild psoriasis and 3854 with severe psoriasis. Respective prevalence rates of risk factors in those with severe psoriasis, mild psoriasis, and in controls were as follows: diabetes (7.1%, 4.4%, 3.3%), hypertension (20%, 14.7%, 11.9%), hyperlipidemia (6%, 4.7%, 3.3%), obesity (20.7%, 15.8%, 13.2%), and smoking (30.1%, 28%, 21.3%). Patients with mild psoriasis had a higher adjusted odds of diabetes (odds ratio [OR], 1.13; 95% confidence interval [CI], 1.08-1.18]), hypertension (OR, 1.03; 95% CI, 1.01-1.06), hyperlipidemia (OR, 1.16; 95% CI, 1.12-1.21), obesity (OR, 1.27; 95% CI, 1.24-1.31), and smoking (OR, 1.31; 95% CI, 1.29-1.34) than controls. Patients with severe psoriasis had a higher adjusted odds of diabetes (OR, 1.62; 95% CI, 1.3-2.01), obesity (OR, 1.79; 95% CI, 1.55-2.05), and smoking (OR, 1.31; 95% CI, 1.17-1.47) than controls. Additionally, diabetes (OR, 1.39; 95% CI, 1.22-1.58) and obesity (OR, 1.47; 95% CI, 1.32-1.63) were more prevalent in those with severe psoriasis than with mild psoriasis.
The study was cross-sectional and therefore the directionality of the associations could not be determined.
Multiple cardiovascular risk factors are associated with psoriasis. Cardiovascular risk factors that are key components of the metabolic syndrome are more strongly associated with severe psoriasis than with mild psoriasis.

Download full-text

Full-text

Available from: Andrea B Troxel, Jan 06, 2014
0 Followers
 · 
135 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Neuronatin (Nnat), which is a neuronal developmental and differentiation molecule, is expressed in the endoplasmic reticulum of non-neuronal cells and is involved in insulin secretion from pancreatic β-cells by plausibly modulating their intracellular calcium concentration. However, the role of Nnat in keratinocyte differentiation remains unclear. To unveil a possible integration of Nnat in controlling the keratinocyte differentiation markers such as involucrin, cytokeratin1, filaggrin, loricrin and S100A7. Immunohistological staining was done using psoriasis, chronic eczema, lichen planus and normal skin. Immunofluorescence staining, Western blotting and semi-quantitative real-time PCR were performed for detecting Nnat, involucrin, cytokeratin1, filaggrin, loricrin and S100A7 using human keratinocytes with or without Nnat gene transfection. Small interference RNA was applied to knockdown the Nnat gene expression. Nnat existed in normal human epidermis and cultured keratinocytes. In the hyperplastic epidermis of psoriasis, chronic eczema and lichen planus, over-expression of Nnat was evident along with involucrin and cytokeratin1 expression. Coordinate up-regulation of Nnat and involucrin, but not cytokeratin1, was demonstrated in cultured keratinocytes under differentiation stimuli such as extracellular calcium elevation, exposure to phorbol myristate acetate, and increased cell density. Transfection of small intereference RNA for Nnat decreased the mRNA levels of Nnat and involucrin, but not of cytokeratin1. Furthermore, a gene transfection assay showed increased involucrin expression in the Nnat-transfected keratinocytes than in mock-transfected counterparts, without any appreciable influence on cytokeratin1, filaggrin, loricrin and S100A7 expression. These data indicate that Nnat is related to keratinocyte differentiation by up-regulating involucrin expression.
    Journal of dermatological science 10/2013; DOI:10.1016/j.jdermsci.2013.10.008 · 3.34 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background. Chronic plaque psoriasis is frequently associated with obesity. The effect of a low-calorie diet on psoriasis has not been investigated. Objective. The objective was to investigate whether moderate weight loss increases the therapeutic response to topical treatment in obese patients with chronic stable plaque-type psoriasis. Material and Method. A 24-week clinical trial was conducted in 10 patients. The efficacy of a low-calorie diet with topical treatment was compared with baseline in obese patients with chronic stable plaque-type psoriasis. The primary measure of clinical response was the Psoriasis Area and Severity Index at weeks 12 and 24. Results. At week 12, the mean reduction in body weight was 9.6 percent. There was an improvement from baseline of 50 percent or more in the Psoriasis Area and Severity Index in 50 percent of the patients. The responses as measured by improvements in the Psoriasis Area and Severity Index were paralleled by improvements in global assessments by the physician and the patients and in the Dermatology Life Quality Index. Conclusion. Obese patients with chronic stable plaque-type psoriasis increase their response to a low-calorie diet. Lifestyle modifications, including a low-calorie diet, may supplement the pharmacologic treatment of obese psoriasis patients.
    Dermatology Research and Practice 09/2013; 2013:795932. DOI:10.1155/2013/795932
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Psoriasis is a chronic inflammatory disorder associated with increased cardiovascular mortality. Psoriasis affects high-density lipoprotein (HDL) composition, generating dysfunctional HDL particles. However, data regarding the impact of anti-psoriatic therapy on HDL composition and function are not available. HDL was isolated from 15 psoriatic patients at baseline and after effective topical and/or systemic anti-psoriatic therapy and from 15 age- and sex-matched healthy controls. HDL from psoriatic patients showed a significantly impaired capability to mobilize cholesterol from macrophages (6.4 vs. 8.0% [(3)H]-cholesterol efflux, P<0.001), low paraoxonase (350 vs. 217 μM/min/mg protein, P=0.011) and increased Lp-PLA2 activities (19.9 vs. 12.1 nM/min/mg protein, P=0.028). Of particular interest, the anti-psoriatic therapy significantly improved (i) serum lecithin-cholesterol acyltransferase activity and decreased total serum lipolytic activity but did not affect serum levels of HDL-cholesterol. Most importantly, these changes were associated with a significantly improved HDL-cholesterol efflux capability. Our results provide evidence that effective anti-psoriatic therapy recovers HDL composition and function, independent of serum HDL-cholesterol levels and support to the emerging concept that HDL function may be a better marker of cardiovascular risk than HDL-cholesterol levels.Journal of Investigative Dermatology accepted article preview online, 28 August 2013. doi:10.1038/jid.2013.359.
    Journal of Investigative Dermatology 08/2013; 134(3). DOI:10.1038/jid.2013.359 · 6.37 Impact Factor